Tech Company Financing Transactions
Ostia Sciences Funding Round
Private investors joined a $730 thousand Seed funding round for Ostia Sciences. This VC investment round was announced on 10/2/2024.
Transaction Overview
Company Name
Announced On
10/2/2024
Transaction Type
Venture Equity
Amount
$730,000
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds to further research and clinical trials, supporting the development of its SALI-10 probiotic, based on its phosphorylated lantibiotic technology, which is ready for clinical trials targeting respiratory and oral diseases in early 2025
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
124 Edward St
Toronto ON, M5G 1G6
Canada
Toronto ON, M5G 1G6
Canada
Phone
Website
Email Address
Overview
At Ostia Sciences Inc., our commitment to health and science drives everything we do. Ostia Sciences' dedication to rigorous and ambitious research and development has led to the creation of Salivaricin 10 and other groundbreaking microbiome solutions that can significantly improve people's health.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Abdelahhad Barbour
Chief Scientific Officer
Michael Glogauer
Browse more venture capital transactions:
Prev: 10/2/2024: poolside venture capital transaction
Next: 10/2/2024: Vizit venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We report on funding rounds that are announced publicly. VC transactions reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs